Research on antibody-drug conjugates is showing promise in treating various types of cancer, including breast cancer with low HER2 expression. The treatment approach is also being explored for use in other cancers, such as non-small-cell lung cancer, urothelial cancer, and bladder cancer. Studies are underway to refine the use of these conjugates, including determining sensitivity and optimal treatment strategies for different types of cancer.